肾小球疾病不同免疫抑制治疗的心血管事件风险评估
该回顾性队列纳入加拿大不列颠哥伦比亚省1912例肾小球疾病患者,评估特定免疫抑制药物暴露与冠状动脉、脑血管及外周动脉复合结局的关联。中位随访6.8年,212例(11.1%)发生主要结局;校正心血管危险因素、疾病类型、eGFR和蛋白尿后,钙调神经磷酸酶抑制剂累积暴露和环磷酰胺累积暴露与心血管事件风险升高相关,而糖皮质激素暴露无显著关联。
要点
- 钙调神经磷酸酶抑制剂累积150-300 DDD和≥300 DDD与心血管事件风险约2倍升高相关。
- 环磷酰胺每累积10克与心血管事件风险升高1.5倍相关。
- 糖皮质激素暴露校正心血管危险因素后与主要结局无显著关联。
核心结论
- 肾小球疾病所用免疫抑制治疗可能具有不同的心血管风险特征,个体化决策时应予考虑,并可作为未来临床试验的安全性终点。
研究设计与样本
- 回顾性队列研究,纳入加拿大不列颠哥伦比亚省1912例肾小球疾病患者(IgA肾病759例、局灶节段性肾小球硬化540例、膜性肾病387例、微小病变226例)。
- 采用生存模型,校正基线心血管危险因素、肾小球疾病类型、随时间变化的eGFR和蛋白尿。
主要发现
- 中位随访6.8年,212例(11.1%)发生主要复合结局(冠状动脉、脑血管和外周动脉事件)。
- 校正心血管危险因素后,糖皮质激素暴露与主要结局无显著关联。
- 完全校正模型中,钙调神经磷酸酶抑制剂累积150-300 DDD与心血管事件风险升高相关(HR 2.98,95%CI 1.27-6.95)。
- 钙调神经磷酸酶抑制剂累积≥300 DDD与心血管事件风险升高相关(HR 2.78,95%CI 1.32-5.84)。
- 完全校正模型中,环磷酰胺每累积10克与心血管事件风险升高相关(HR 1.46,95%CI 1.22-1.75)。
关键数值与推荐
- 抗代谢药(硫唑嘌呤、吗替麦考酚酯和麦考酚钠)峰值日剂量≥0.5 DDD在校正基线危险因素和疾病类型后与心血管事件风险升高相关,但校正随时间变化的eGFR和蛋白尿后关联不显著(HR 1.70,95%CI 0.91-3.20)。
临床怎么用
- 在决定肾小球疾病患者免疫抑制方案时,应结合个体心血管风险特征考虑不同药物的心血管安全性差异。
- 对需使用钙调神经磷酸酶抑制剂或环磷酰胺的患者,尤其累积剂量较高者,应加强心血管风险监测与管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with glomerular disease are at high risk of cardiovascular disease but the contribution of immunosuppression to this risk is unclear. In this retrospective cohort study of 1912 patients (comprised of 759 with IgA nephropathy, 540 with focal segmental glomerulosclerosis, 387 with membranous nephropathy and 226 with minimal change disease) from British Columbia, Canada, we evaluated the association between exposure to specific immunosuppressive medications and a composite outcome including coronary artery, cerebrovascular and peripheral arterial events. Survival models were adjusted for baseline cardiovascular risk factors, type of glomerular disease, estimated glomerular filtration rate (eGFR) and proteinuria over time. During a median follow-up of 6.8 years, 212 patients (11.1%) experienced the primary outcome. Corticosteroid exposure was not significantly associated with the primary outcome after adjusting for cardiovascular risk factors. In fully adjusted models, cumulative calcineurin inhibitor exposure at modest (150-300 defined daily doses [DDD]) and higher (300 or more DDD) doses were associated with a 2-fold higher risk of cardiovascular events (hazard ratio 2.98, 95% confidence interval 1.27-6.95) and (2.78, 1.32-5.84), respectively. A peak daily dose of antimetabolite (azathioprine, mycophenolate mofetil and mycophenolate sodium) of 0.5 or more DDD was associated with higher risk of cardiovascular events after adjustment for baseline risk factors and type of glomerular disease, but not after adjusting for time-varying eGFR and proteinuria (1.70, 0.91-3.20). Each 10 grams of cumulative cyclophosphamide exposure was associated with a 1.5-fold higher risk of cardiovascular events in a fully adjusted model (1.46, 1.22-1.75) Thus, our findings suggest that immunosuppressive therapies used in the treatment of glomerular disease may have different cardiovascular risk profiles, which should be considered when deciding on immunosuppression for individual patients and as a safety endpoint in future clinical trials.
引用
- Canney M, Atiquzzaman M, Zheng Y, et al. Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases. Kidney Int. 2024. PMID: 39515645. doi:10.1016/j.kint.2024.10.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。